Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NeurogesX closes Series C private placement

Executive Summary

NeurogesX (neuropathic pain therapeutics) raised $35mm through the closing of its Series C venture round. New investor Global Life Science Ventures led the placement, and was joined by Diamond Capital Management (representing Dow Employees' Pension Plan and Union Carbide Employees' Pension Plan) and existing investors Alta Partners, Arch Venture Partners, Montreux Equity Partners, Walden International, the Teachers Insurance and Annuity Association, and the University of North Carolina.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies